Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Key Takeaways from the Bispecific Antibody Competitive Landscape Report Key Takeaways from the Bispecific Antibody Competitive Landscape Report Request a sample and discover the recent advances in bispecific antibody treatment @Bispecific Antibody Competitive Landscape Report Bispecific Antibody Overview Bispecific antibodies have been developed, with one antigen-binding site directed against the CD3 receptor (which activates cytotoxic T lymphocytes) and the other directed...

Key Takeaways from the Bispecific Antibody Competitive Landscape Report

Request a sample and discover the recent advances in bispecific antibody treatment @ Bispecific Antibody Competitive Landscape Report

Bispecific Antibody Overview

Bispecific antibodies have been developed, with one antigen-binding site directed against the CD3 receptor (which activates cytotoxic T lymphocytes) and the other directed against tumor cell antigens (CD19, CD20, CD33, CD123, HER2, epithelial cell adhesion molecule [EpCAM], BCMA, CEA, and others). The interaction with cytotoxic T lymphocytes and tumor cells caused by Bispecific antibody binding stimulates cytotoxic T cells and enhances tumor cell death. Several bispecific molecules for the treatment of different diseases have been produced in addition to a large spectrum of bispecific antibodies directed against tumors. The osteoporosis bispecific antibody inhibits the Wnt signal-transduction pathway factors (sclerostin and Dkk1), promoting osteoblast development and bone tissue growth.

Bispecific antibodies have various advantages over monospecific antibodies. Bispecific antibodies lead immune system effectors to tumor cells, increasing their cytotoxicity. Bispecific antibodies have higher binding specificity than monospecific antibodies because they engage with two separate surface antigens. When compared to combination therapy with two monospecific medicines, the use of bispecific antibodies allows for cost optimization by lowering the cost of development and clinical trials.

Find out more about bispecific antibody drugs @ Bispecific Antibody Treatment

Bispecific Antibody Pipeline Analysis: Drug Profile

Ivonescimab: Akeso

Ivonescimab, also known as AK112 in China and Australia and SMT112 in the Licence Territories, is a new, potentially first-in-class bispecific antibody that the Company created independently. Ivonescimab combines the immunotherapy benefits of PD-1 blockage with the anti-angiogenesis properties of an anti-VEGF into a single drug. The unique design, we believe, has the potential to lessen side effects and safety concerns. Ivonescimab is thought to be the most advanced PD-1 / VEGF bispecific antibody in the clinic: no known PD-1-based bispecific antibodies have been licensed by the FDA or the EMA. 

Akeso is currently running a phase III clinical research comparing ivonescimab monotherapy to pembrolizumab monotherapy as a first-line treatment for NSCLC patients with positive PD-L1 expression. In addition, phase III clinical research comparing Ivonescimab with chemotherapy to chemotherapy in EGFR-mutated advanced non-squamous NSCLC that had previously failed EGFR-TKI therapy is now underway. The NMPA has granted ivonescimab breakthrough therapy designation status in China for three indications: the two aforementioned indications, as well as when combined with docetaxel for the treatment of patients with locally advanced or metastatic NSCLC who have failed prior PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.

Zanidatamab: Zymeworks

Zanidatamab is a bispecific antibody based on Zymeworks' Azymetric platform that can bind two non-overlapping HER2 epitopes at the same time, a process known as biparatopic binding. This one-of-a-kind design results in a variety of modes of action, including dual HER2 signal blockage, enhanced binding and removal of HER2 protein from the cell surface, and potent effector function, all of which contribute to encouraging anticancer activity in patients. Zymeworks is testing zanidatamab in several Phase I, Phase II, and pivotal clinical trials around the world as a targeted therapeutic option for patients with HER2-positive solid tumors.

A snapshot of the Bispecific Antibody Pipeline Drugs mentioned in the report:

 

Learn more about the emerging bispecific antibody pipeline drugs @ Bispecific Antibody Clinical Trials

Scope of the Bispecific Antibody Competitive Landscape Report 

Dive deep into rich insights for new bispecific antibody drugs, visit @ Bispecific Antibody Drugs

Table of Contents

 

For further information on the bispecific antibody pipeline therapeutics, reach out @ Bispecific Antibody Analysis

Related Reports

Monoclonal Antibodies Competitive Landscape

Monoclonal Antibodies Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key monoclonal antibody companies, including Novartis, Gmax Biopharm, Omeros Corporation, Merck Sharp & Dohme, Disc Medicine, Eledon Pharmaceuticals, Alexion AstraZeneca Rare Disease, Chinook Therapeutics, Omeros Corporation, among others.

PD-1 and PD-L1 Inhibitors Competitive Landscape

PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, among others.

JAK Inhibitors Competitive Landscape

JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.

TIGIT Inhibitors Competitive Landscape

TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868690.html